Hyperinsulinaemic hypoglycaemia is a complex condition where the pancreas produces too much insulin, causing dangerously low blood sugar levels. Early and accurate diagnosis is crucial to prevent permanent brain damage, especially in infants and children.

Introduction: When to Seek Diagnostic Testing

Diagnostic testing for hyperinsulinaemic hypoglycaemia becomes necessary when someone experiences signs of low blood sugar that don’t have an obvious cause. This condition can affect both newborns and older children, though the timing and severity vary greatly from person to person. In newborns, testing is particularly urgent when a baby shows poor feeding, unusual skin color changes such as paleness or a bluish tint around the mouth, breathing problems, shaking movements, or seizures. These symptoms demand immediate medical attention because the developing brain is extremely vulnerable to damage from low glucose levels.

For older children and occasionally adults, the warning signs might include extreme hunger at unusual times, sudden weakness, excessive sweating, rapid heartbeat, confusion, headaches, or episodes of shaking. Some children may experience symptoms after eating, while others have problems during periods without food. Parents should seek diagnostic evaluation if their child has repeated episodes of these symptoms, especially if eating something sweet provides quick relief. Children who are unusually irritable, have difficulty concentrating, or show behavioral changes alongside physical symptoms should also be evaluated.

Certain situations increase the likelihood of developing hyperinsulinaemic hypoglycaemia and warrant earlier testing. Babies born to mothers with diabetes, those who experienced stress during birth such as lack of oxygen, premature infants, and babies who are either much larger or smaller than expected for their gestational age face higher risks. Additionally, infants with certain genetic syndromes, particularly Beckwith-Wiedemann syndrome, should be screened even without obvious symptoms. Family history matters too—if close relatives have had similar problems with low blood sugar in infancy or childhood, diagnostic testing should be considered promptly when any concerning symptoms appear.

Classic Diagnostic Methods

Diagnosing hyperinsulinaemic hypoglycaemia requires careful documentation of specific blood test results obtained at the exact moment when blood sugar drops below normal levels. This timing is critical because the pattern of hormone levels during hypoglycaemia reveals whether insulin is inappropriately high. The fundamental diagnostic approach follows what doctors call Whipple’s triad—three conditions that must all be present: symptoms consistent with low blood sugar, a measured blood glucose concentration below the normal range, and resolution of symptoms when blood sugar is corrected. However, for hyperinsulinaemic hypoglycaemia, additional blood tests taken during the low blood sugar episode are essential.

The key diagnostic criteria include finding a plasma glucose level below 3 millimoles per liter (or 55 milligrams per deciliter) alongside detectable levels of insulin and C-peptide in the blood. C-peptide is a substance released along with insulin by the pancreas, so its presence confirms that the insulin is being made by the body rather than injected from outside. At the same time, blood levels of ketone bodies and fatty acids should be inappropriately low. This pattern is distinctive—normally, when blood sugar drops, insulin production stops completely, allowing the body to break down fat and produce ketones as alternative fuel. In hyperinsulinaemic hypoglycaemia, insulin remains present despite low blood sugar, preventing this protective response.

Another strong indicator is the amount of intravenous glucose required to maintain normal blood sugar levels. Children with hyperinsulinaemic hypoglycaemia typically need glucose infusion rates greater than 8 milligrams per kilogram of body weight per minute to keep their blood sugar stable. This is significantly higher than the normal requirement of 4 to 6 milligrams per kilogram per minute. When doctors observe that a child needs such high glucose delivery rates, it strongly suggests excessive insulin activity.

To properly capture these diagnostic measurements, healthcare providers often perform what’s called a controlled fast. This supervised test involves withholding food while closely monitoring the patient in a hospital setting. For newborns and young infants, the fast may need to last only a few hours before hypoglycaemia develops, whereas older children might fast overnight or longer. Throughout the fast, medical staff check blood sugar levels frequently using fingerstick tests, and when the glucose drops below a certain threshold, they immediately draw blood samples for the comprehensive panel of tests. This includes measuring insulin, C-peptide, ketone bodies, fatty acids, and sometimes additional hormones to rule out other causes of low blood sugar.

Blood samples must be processed correctly to ensure accurate results. Some hormones break down quickly after blood is drawn, so samples need to be placed on ice and sent to the laboratory promptly. The insulin measurement is particularly sensitive—if the sample isn’t handled properly, the results can be misleading. This is why diagnosis usually requires specialized pediatric endocrinology centers with experience in these testing protocols.

Beyond the biochemical tests, doctors also perform genetic testing when hyperinsulinaemic hypoglycaemia is confirmed. Multiple genes are known to cause this condition, including ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, HNF4A, HNF1A, and several others. Identifying the specific genetic mutation helps predict how severe the condition will be, whether it might resolve over time, and how well it will respond to different medications. For example, mutations in the ABCC8 and KCNJ11 genes, which affect potassium channels in pancreatic cells, typically cause the most severe forms that don’t respond to standard medications.

Distinguishing hyperinsulinaemic hypoglycaemia from other causes of low blood sugar is another crucial aspect of diagnosis. Many conditions can cause hypoglycaemia in children, including hormone deficiencies affecting growth hormone or cortisol, metabolic disorders that prevent the body from properly processing nutrients, and various genetic conditions. The distinctive biochemical pattern—low blood sugar with detectable insulin and suppressed ketones—helps differentiate hyperinsulinaemic hypoglycaemia from these other causes. Additional tests may include measurements of growth hormone, cortisol, and other metabolic markers to rule out alternative diagnoses.

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials investigating new treatments for hyperinsulinaemic hypoglycaemia, additional diagnostic procedures and standardized testing protocols are typically required. Clinical trials demand very precise documentation and often use stricter criteria than routine clinical care to ensure that study results are accurate and comparable across different research centers. Understanding these requirements helps families know what to expect if their child is being evaluated for trial participation.

Most clinical trials require confirmation of diagnosis through standardized biochemical testing performed at specific accredited laboratories. The core diagnostic tests remain the same—documented hypoglycaemia with simultaneously measured insulin, C-peptide, ketones, and fatty acids—but trials often specify exact glucose cutoff values and may require the tests to be repeated to confirm consistency. For instance, a trial might require at least two separate episodes of documented hypoglycaemia meeting specific biochemical criteria before a patient is considered eligible. This repetition helps ensure that the diagnosis is solid and not based on a single unusual test result.

Genetic testing becomes particularly important for clinical trial qualification because many trials focus on specific genetic subtypes of hyperinsulinaemic hypoglycaemia. Some studies only enroll patients with mutations in particular genes, such as those affecting the KATP channel (ABCC8 or KCNJ11 genes), while others might specifically target patients with mutations affecting different metabolic pathways. Genetic analysis must usually be performed at certified laboratories using validated testing methods, and the results need to be documented in medical records before enrollment can proceed. Families should understand that if initial genetic testing at their local hospital didn’t identify a mutation, more comprehensive genetic sequencing might be requested as part of trial screening.

Imaging studies form another component of diagnostic evaluation for clinical trials, particularly when surgical treatment might be involved. The most important imaging technique is 18F-DOPA PET-CT scanning, a specialized nuclear medicine test that can distinguish between two main forms of congenital hyperinsulinism: diffuse disease, where all pancreatic beta cells throughout the pancreas are affected, and focal disease, where only a small area of abnormal tissue causes the problem. This distinction is crucial because focal disease can potentially be cured by surgically removing just the affected area, while diffuse disease involves the entire pancreas. Clinical trials testing medical treatments might require PET-CT imaging to confirm that participants have diffuse disease, since these patients benefit most from medication rather than surgery. The test involves injecting a small amount of radioactive material that concentrates in areas of overactive insulin secretion, allowing doctors to see precisely where the problem lies.

Trials often include baseline assessments of how well current treatments are working before enrolling patients. This might involve detailed glucose monitoring over several days or weeks, documenting the frequency and severity of hypoglycaemic episodes, and recording the doses of all medications being used. Continuous glucose monitoring systems, which measure blood sugar levels automatically throughout the day and night, may be used to provide comprehensive data on glucose patterns. Additionally, trials typically document the glucose infusion rate needed to maintain normal blood sugar levels, as this provides an objective measure of disease severity that can be tracked over time to assess whether experimental treatments are effective.

Medical history documentation for clinical trials is more extensive than routine care. Research coordinators will ask detailed questions about when symptoms first appeared, how the diagnosis was made, what treatments have been tried, how the child responded to each medication, any surgeries performed, developmental milestones, episodes of severe hypoglycaemia requiring emergency treatment, and any other medical conditions. Family medical history is explored thoroughly, including asking about relatives who may have had similar problems, diabetes at young ages, or unexplained deaths in infancy. This comprehensive history helps ensure patients are appropriately matched to trials and provides baseline information against which treatment effects can be measured.

Assessment of brain function and development is commonly included in trial protocols, particularly for studies in young children where preventing developmental delay is a key goal. This might include formal neurodevelopmental testing performed by specialists, brain imaging studies such as MRI scans to look for any existing injury from past hypoglycaemia, and ongoing monitoring of developmental milestones throughout the trial. Some studies track cognitive abilities, learning skills, and behavior over time to determine whether maintaining better glucose control through new treatments leads to better outcomes. These assessments help researchers understand not just whether a treatment lowers the frequency of hypoglycaemic episodes, but whether it genuinely improves long-term health and quality of life.

Participation in clinical trials often requires more frequent blood tests and clinic visits than standard care. Patients might need blood drawn weekly or even more often during certain phases of the study, attend appointments at the research center every few weeks, and maintain detailed logs of symptoms, blood glucose measurements, food intake, and medication doses. The research team will explain exactly what’s required before enrollment so families can make informed decisions about whether participation is feasible given their circumstances. While this represents a significant commitment, many families find that the extra monitoring and attention actually provides reassurance and helps optimize their child’s care, regardless of whether the experimental treatment proves effective.